SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?

被引：0

作者：

Diaconu, Camelia ^{[1
,2
]}

Salmen, Teodor ^{[3
]}

Gaman, Mihnea A. ^{[1
]}

Bratu, Ovidiu G. ^{[1
,4
,5
]}

Mischianu, Dan ^{[1
,4
,5
]}

Marcu, Radu D. ^{[1
,4
]}

Suceveanu, Andra I. ^{[6
]}

Costache, Raluca S. ^{[4
]}

Stoian, Anca Pantea ^{[1
]}

机构：

[1] Carol Davila Univ Med & Pharm, Bucharest, Romania

[2] Clin Emergency Hosp Bucharest, Bucharest, Romania

[3] NC Paulescu Natl Inst Diabet Nutr & Metab Dis, Bucharest, Romania

[4] Univ Emergency Cent Mil Hosp, Bucharest, Romania

[5] Acad Romanian Scientists, Bucharest, Romania

[6] Ovidius Univ, Fac Med, Constanta, Romania

来源：

ROMANIAN JOURNAL OF MILITARY MEDICINE | 2019年 / 122卷 / 01期

关键词：

SGLT2; inhibitors; type; 2; diabetes; empagliflozin; canagliflozin; heart failure; HEART-FAILURE; OUTCOMES; RISK; EMPAGLIFLOZIN; MECHANISMS;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Two major trials, EMPA-REG OUTCOME trial (with Empagliflozin) and CANVAS trial (with Canagliflozin) have demonstrated the beneficial effects of SGLT2 inhibitors in patients with type 2 diabetes at risk for heart failure. SGLT2 inhibitors possess a unique pharmacological profile and have shown a significant reduction of hospitalization for heart failure in diabetic patients, immediately after treatment commencement. It seems that their effects are beneficial both in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. SGLT2 inhibitors reduce cardiovascular endpoints in patients with diabetes and high cardiovascular risk, most likely through a reduction of heart failure-related events. Empagliflozin treatment exerts beneficial effects on vascular function and central haemodynamics. Various mechanisms seem to contribute to the beneficial effects of SGLT2 inhibitors in heart failure. Taking into consideration their cardiovascular benefits and the number of ongoing trials with these drugs, there is a possibility to expand their indication to nondiabetic patients with heart failure. This review focuses on the newest insights into the beneficial effects of SGLT2 inhibitors on the cardiovascular system.

引用

页码：16 / 21

页数：6

共 32 条

[1]

Abdelgadir Elamin, 2018, J Clin Med Res, V10, P615, DOI 10.14740/jocmr3467w

[2] DPP-4 inhibitors [J].

Ahren, Bo .

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 21 (04) :517-533

[3] Mechanisms of the glycaemic effects of sulfonylureas [J].

Ashcroft, FM .

HORMONE AND METABOLIC RESEARCH, 1996, 28 (09) :456-463

[4]

Bailey C.J., 2010, Br. J. Diabetes Vasc. Dis, V10, P193, DOI [10.1177/1474651410377832, DOI 10.1177/1474651410377832]

[5] Heart failure - The frequent, forgotten, and often fatal complication of diabetes [J].

Bell, DSH .

DIABETES CARE, 2003, 26 (08) :2433-2441

[6] Blood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis [J].

Emdin, Connor A. ;

Rahimi, Kazem ;

Neal, Bruce ;

Callender, Thomas ;

Perkovic, Vlado ;

Patel, Anushka .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (06) :603-615

[7]

Espeland M, 2007, DIABETES CARE, V30, P1374

[8] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Hantel, Stefan ;

Salsali, Afshin ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. ;

Mortelmans, J. .

EUROPEAN HEART JOURNAL, 2016, 37 (19) :1526-1534

[9]

Greenfield JR., 2004, Aust Prescr, V27, P67, DOI [10.18773/austprescr.2004.059, DOI 10.18773/AUSTPRESCR.2004.059]

[10] Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis [J].

Htike, Zin Z. ;

Zaccardi, Francesco ;

Papamargaritis, Dimitris ;

Webb, David R. ;

Khunti, Kamlesh ;

Davies, Melanie J. .

DIABETES OBESITY & METABOLISM, 2017, 19 (04) :524-536

← 1 2 3 4 →